Souhaitez-vous accéder aux communiqués récents ?

Longeveron announces Data Monitoring Committee for Phase 2b clinical trial in HLHS completed a risk-benefit assessment and recommended continuation.

Longeveron announced that a constructive Type C meeting with the U.S. FDA was held to discuss the ongoing development of laromestrocel in HLHS.

Longeveron will report 2026 first quarter financial results and provide a business update on Wednesday, May 13, 2026.

China National Intellectual Property Administration has granted a patent covering potency assay methods for assessing human mesenchymal stem cells (MSCs).

Longeveron reported financial results for the year ended December 31, 2025 and provided a business update. Results from pivotal P2 trial anticipated 3Q26.

Longeveron to report 2025 full year financial results and provide a business update on March 17, 2026 after the U.S. financial markets close.

Longeveron announces closing of previously announced up to $30 million private placement.

Longeveron announces private placement financing of up to $30 million.

Results of Phase 2b clinical trial demonstrating stem cell therapy improved condition of patients with aging frailty published in Cell Stem Cell journal.

Longeveron (LGVN) has appointed Stephen H. Willard as Chief Executive Officer.